A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.
A novel antibody therapy fights certain blood cancers effectively while avoiding severe immune reactions, opening a safer path for heavily treated patients.
PSB202, a first-in-class bifunctional antibody targeting both CD20 and CD37, demonstrated a manageable safety profile and 30% ORR in heavily pretreated R/R B-NHL patients in a Phase Ia trial, notably achieving B-cell depletion without cytokine release syndrome by avoiding T-cell engagement. Single-cell sequencing revealed distinct immune microenvironment patterns between responders and non-responders, supporting further clinical development of this T-cell-independent approach.
What the study was
- Study design
- Phase Ia dose-escalation trial (NCT05003141)
- Population
- Adults with relapsed/refractory CD20+ B-cell non-Hodgkin lymphoma; heavily pretreated (multicenter China + international)
- Sample size
- 15
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of hematology & oncology
Why it surfaced
First-in-class mechanism (T-cell independent CD20+CD37 dual depletion) addresses CD3-toxicity limitation of bispecific antibodies. Phase Ia with very small n=15; ORR 30% is modest but early. High novelty, early stage. Scored at ceiling for Phase I given mechanism interest.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.